ORIGINAL RESEARCH

Effect of rovatirelin in patients with cerebellar ataxia: two randomised double-blind placebo-controlled phase 3 trials

Masatoyo Nishizawa,1, Osamu Onodera,2 Akihiro Hirakawa,3 Yoshitaka Shimizu,4 Masayuki Yamada,5 on behalf of the Rovatirelin Study Group

ABSTRACT

Objective To investigate the efficacy of rovatirelin, a thyrotropin-releasing hormone analogue, for ataxias in patients with spinocerebellar degeneration (SCD).

Methods Two multicentre, randomised, double-blind, placebo-controlled phase 3 studies (KPS1301, KPS1305) enrolled patients with predominant cerebellar ataxia, including SCA6, SCA31 or cortical cerebellar atrophy. KPS1301 enrolled patients with truncal ataxia and KPS1305 enrolled patients with truncal and limb ataxia. Each study included 4 weeks of pretreatment, a 28-week or 24-week treatment period and 4 weeks of follow-up. Patients were randomised (1:1:1) to rovatirelin (1.6 or 2.4 mg) or placebo in KPS1301, and randomised (1:1) to rovatirelin 2.4 mg or placebo in KPS1305. The primary endpoint was change in Scale for the Assessment and Rating of Ataxia (SARA) total scores. Pooled analysis was performed in patients who met the SARA recruitment criteria of KPS1305.

Results From October 2013 to May 2014, KPS1301 enrolled 411 patients; 374 were randomised to rovatirelin 1.6 mg (n=125), rovatirelin 2.4 mg (n=126) or placebo (n=123). From November 2016 to August 2017, KPS1305 enrolled 241 patients; 203 were randomised to rovatirelin 2.4 mg (n=101) or placebo (n=102). The primary endpoint showed no significant difference between rovatirelin and placebo in these two studies. In the pooled analysis (n=278), the difference between rovatirelin 2.4 mg (n=140) and placebo (n=138) was −0.61 (−1.64 vs −1.03; 95% CI −1.16 to −0.06; p=0.029) in the adjusted mean change in the SARA total score.

Conclusions Rovatirelin is a potentially effective treatment option for SCD.

Trial registration number NCT01970098; NCT02889302

INTRODUCTION

Spinocerebellar degeneration (SCD) is a neurodegenerative disease that is characterised by progressive cerebellar ataxia.1 2 The main symptoms of SCD are gait ataxia, standing instability, limb ataxia and dysarthria.3 In addition, pyramidal tract, extrapyramidal or peripheral nervous symptoms can occur in patients with some types of SCDs.3 Hereditary SCA6, SCA31 and sporadic cortical cerebellar atrophy (CCA) mainly show cerebellar symptoms, while hereditary SCA1, SCA2, SCA3 (Machado-Joseph disease) and sporadic multiple system atrophy (MSA) show cerebellar symptoms and extracerebellar symptoms. The presence of extracerebellar symptoms also contributes to a patient’s disability and may interfere with evaluation of the severity of cerebellar ataxia. Therefore, it is considered more useful to evaluate the effect of a drug on cerebellar ataxia in patients with predominant cerebellar symptoms.

Thyrotropin-releasing hormone (TRH) is a hypothalamic hormone that promotes thyroid-stimulating hormone and prolactin (PRL) release from the pituitary gland, and acts broadly on the central nervous system to activate several neurotransmitters.4 7 TRH has been shown to improve ataxia in an ataxia mouse model with a CACNA1A mutation, the causative gene for SCA6.8 9 In a 2-week, double-blind, placebo-controlled trial in 254 SCD patients, the efficacy of a TRH analogue (TRH tartrate) was demonstrated in patients with predominantly ataxic forms of SCD.10 Thus, the first TRH analogue was approved in Japan in 1985 for the treatment of ataxia associated with SCD. However, in the previous clinical trial, the diagnostic criteria for SCD were not consistent with recent diagnostic criteria. Further, over 60% of patients with the predominantly ataxic forms of SCD had olivoponto cerebellar atrophy, and the drug effects were not assessed using an ataxia rating scale alone. Finally, the duration of the trial was only 2 weeks. Therefore, well-designed double-blind trials were considered necessary to demonstrate the efficacy of new drug candidates for cerebellar ataxia.11 12

Rovatirelin is a new TRH analogue,13 which showed higher affinity for human TRH receptors and greater absorption and transition into and stability in the brain than the existing TRH analogue, talirelin.14 15 The effects of rovatirelin on the ataxic rolling Nagoya mice, which carry a mutation in the CACNA1A gene, were more potent and lasted longer than those of talirelin (data on file). To investigate the efficacy and safety of rovatirelin for the treatment of cerebellar ataxia, we performed two large-scale, randomised, double-blind, phase 3 studies in patients with predominant cerebellar symptoms of SCD.

METHODS

Study design and participants

Two similar multicentre, randomised, double-blind, placebo-controlled, phase 3 studies (KPS1301...
and KPS1305) were conducted in Japanese patients with SCD. Patients were enrolled from 86 hospitals in Japan between 9 October 2013 and 30 May 2014 in KPS1301 and from 62 hospitals in Japan between 15 November 2016 and 1 August 2017 in KPS1305.

Both studies included patients aged ≥20 years with only predominant cerebellar symptoms of SCD (CCA or genetically confirmed SCA6 or SCA31). The diagnosis of CCA was mainly based on the idiopathic cerebellar ataxia diagnostic criteria proposed by Yoshida et al. Briefly, patients with slowly progressive adult-onset cerebellar ataxia and with no first-degree or second-degree relatives with ataxia were enrolled, while patients with autoimmune-mediated, metabolic, alcoholic and drug-induced ataxia were excluded. In addition, patients with MSA were carefully excluded based on the second consensus statement for the diagnosis of MSA. A detailed diagnostic flow diagram of CCA is shown in online supplementary figure 1.

The KPS1301 study included patients with truncal ataxia (Scale for the Assessment and Rating of Ataxia (SARA) total score of ≥6 and SARA gait score of 2–6). The KPS1305 study included patients with both truncal and limb ataxia (SARA gait score of 2–6, stance score of ≥2 and scores of ≥1 for the finger chase, nose–finger and fast alternating hand movements tests (patients with scores of ≥1 on unilateral tests were included if tests were not feasible on the right or left side for some reason other than the primary disease)).

Exclusion criteria were: secondary ataxia (eg, cerebrovascular disorder, brain tumour, multiple sclerosis, hypothyroidism, drug-induced, paraneoplastic syndrome); suspected alcoholic ataxia; motor disorder due to musculoarticular disease; cognitive impairment, depression or other mental diseases and a diagnosis of thyrotoxicosis. In the KPS1305 study, patients who had participated in a rovatirelin study ≥2 years ago were eligible to enrol; however, this group of patients was restricted to ≤30% of the total number of patients enrolled in KPS1305.

Randomisation and masking
Patients were randomised using an Interactive Web Response System by an independent organisation. They received rovatirelin 1.6 mg, rovatirelin 2.4 mg or placebo (1:1:1) in the KPS1301 study, and rovatirelin 2.4 mg or placebo (1:1) in the KPS1305 study. In KPS1305, the presence/absence of participation in a previous clinical study of rovatirelin was included as a stratification factor for dynamic allocation. All patients and personnel involved in the study, including the investigators and study-site staff, were masked to the treatment assignment. The test agents were indistinguishable from one another, and indistinguishability was confirmed at the time of test agent allocation and at the end of the study. Results of the endocrinology tests were stored at the measuring institution until unblinding.

Procedures
Both studies included a single-blind 4-week pretreatment period, during which only the patients were blinded and were given oral placebo once daily after breakfast. Thereafter, under double-blind conditions, eligible patients received oral rovatirelin or placebo once daily (after breakfast) for 28 weeks (KPS1301) or 24 weeks (KPS1305). In a follow-up period of 4 weeks, the patients were given no test agents and underwent only safety evaluation. TRH analogues, CYP3A4 inhibitors and P-glycoprotein inhibitors were prohibited during the pretreatment and treatment periods. In addition, investigational products other than rovatirelin were prohibited throughout the study.

Efficacy and safety were evaluated during hospital visits every 4 weeks. At weeks 0 through 24, SARA (Japanese version) was used to assess the degree of ataxia. Each patient was assessed for SARA by the same investigator, who was a board-certified neurologist of the Japanese Society of Neurology. Because differences in SARA assessment between investigators cannot be eliminated in large-scale, multicentre trials, the investigators were trained using a video of the SARA assessment method to reduce the variability in SARA assessments. Patient quality of life (QoL) was self-assessed using the Japanese version of the Short Form-8 (SF-8) questionnaire at weeks 0 through 24.

Outcomes
The primary endpoint was change in the SARA total score from baseline to the time point of final evaluation. The final evaluation was defined as the latest evaluation, excluding missing data. Secondary efficacy endpoints were the SARA total score, individual SARA scores and SF-8 scores at each evaluation time point. Safety endpoints included adverse events (AEs), vital signs, body weight, 12-lead ECG, clinical laboratory tests and endocrinology tests (thyroid stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4) and PRL). Investigators evaluated AEs for severity (mild, moderate or severe) and for causal relationships with the test agents.

Statistical analyses
For the KPS1301 study, assuming a difference in the change in the SARA total score between the rovatirelin group and the placebo group of −0.75, and a common SD of 2.0, a sample size of 113 randomly assigned patients was calculated as sufficient to provide 80% power with a two-sided 5% significance level. In the KPS1305 study, a sample size of 87 randomly assigned patients was calculated as sufficient to provide 80% power with a two-sided 5% significance level, assuming a difference in the change in the SARA total score between the rovatirelin 2.4 mg group and the placebo group of −1.06 and a common SD of 2.48.

The full analysis set, which was used for efficacy analysis, excluded patients who were untreated or ineligible, violated the Good Clinical Practice (GCP), discontinued before the beginning of the treatment period or were unavailable for the primary endpoint. The safety set, which was used for safety analysis, excluded patients who violated the GCP, were untreated or discontinued before the beginning of the treatment period.

The primary endpoint in both studies and the pooled analysis was calculated as the difference in SARA total score between the final evaluation and week 0 (the end of the pretreatment period). The change in SARA total score between the two groups was compared using analysis of covariance, with the treatment group as the fixed effect and the SARA total score at week 0 as the covariate in KPS1301. The presence/absence of participation in a previous clinical study of rovatirelin was also included in KPS1305. In KPS1301, a closed testing procedure was used for adjustment of multiplicity, and superiority of rovatirelin 1.6 mg over placebo was verified only after superiority of rovatirelin 2.4 mg over placebo was confirmed.

We hypothesised that patients with less severe ataxia show a more prominent placebo effect. Therefore, a subgroup analysis of the primary endpoint was performed in patients in the KPS1301 study who met the KPS1305 inclusion criteria (SARA gait score of 2–6, stance score of ≥2 and scores of ≥1 for the finger chase, nose–finger and fast alternating hand movements tests).

2 Nishizawa M, et al. J Neurol Neurosurg Psychiatry 2020;0:1–9. doi:10.1136/jnnp-2019-322168

J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2019-322168 on 14 January 2020. Downloaded from http://jnnp.bmj.com/ on July 9, 2020 by guest. Protected by copyright.
A pooled retrospective analysis was performed that combined the data from the above subgroup of KPS1301 and from all patients in KPS1305 with the same inclusion criteria (SARA gait score of 2–6, stance score of ≥2 and scores of ≥1 for the finger chase, nose–finger and fast alternating hand movements tests). The patients who received either rovatirelin 2.4 mg or placebo and had not participated in a previous rovatirelin study were included. Furthermore, in the pooled analysis, two subgroup analyses were also performed in patients with a baseline SARA total score of ≥15 and <15, because the median baseline SARA total score in the pooled group was 15.

The significance level for each two-sided statistical testing was 5%. In the comparison of efficacy variables between the two groups, two-sample t-tests were used for continuous variables. All analyses used SAS V9.4 (SAS Institute).

RESULTS

Patient population

In the KPS1301 study, 411 patients with truncal ataxia were enrolled; 374 of these patients were included in the safety set and 369 in the full analysis set (figure 1A). In the KPS1305 study, 241 patients with truncal and limb ataxia were enrolled; 203 were included in the safety set and 202 in the full analysis set (figure 1B). The pooled analysis included 278 patients; 140 in the rovatirelin 2.4 mg group and 138 in the placebo group. In both studies, there were no major between-group differences in baseline characteristics (table 1). In KPS1301, 165 patients had SCA6, 72 patients had SCA31 and 132 patients had CCA; respective numbers in KPS1305 were 83 (SCA6), 57 (SCA31) and 62 (CCA) patients. The mean baseline SARA total score was 12.9 in KPS1301 and 14.9 in KPS1305. In addition, the mean baseline SARA total score was lower for patients with truncal and limb ataxia in the KPS1305 study versus patients with truncal and limb ataxia in the KPS1301 study (14.9 vs 16.8, p<0.001, two-sample t-test). The SARA total scores during the pretreatment period were stable for patients who received treatment in the two trials (n=577; change in SARA total score during the pretreatment period: 0.04±1.59, mean±SD, p=0.530, one-sample t-test).

Treatment was discontinued in KPS1301 by 16.0% of patients receiving rovatirelin 1.6 mg, 19.8% of patients receiving 2.4 mg and 4.9% of patients receiving placebo (figure 1A). In KPS1305, treatment was discontinued by 9.9% of patients in the rovatirelin 2.4 mg group and 11.8% of patients in the placebo group (figure 1B). The main reasons for the discontinuation were AEs and worsening of ataxia (figure 1).

Efficacy

In KPS1301, the adjusted mean change in SARA total score at the final evaluation time point (primary endpoint) was −0.74 for rovatirelin 1.6 mg, −1.23 for rovatirelin 2.4 mg and −1.16 for placebo; the difference between rovatirelin 2.4 mg and placebo (−0.07; 95% CI −0.64 to 0.49) was not significant (p=0.800, figure 2A).

In the subgroup of patients with limb and truncal ataxia (n=13690, online supplementary table 1), the adjusted mean change in SARA total score at the final evaluation time point was −0.65 for rovatirelin 1.6 mg, −1.98 for rovatirelin 2.4 mg and −0.92 for placebo. In this subgroup, the difference between...
### Table 1  Baseline demographics and characteristics of the full analysis set

|                          | KPS1301 study | KPS1305 study | Pooled group* |
|--------------------------|---------------|---------------|---------------|
|                          | Placebo (n=123) | Rovatirelin 1.6 mg (n=124) | Rovatirelin 2.4 mg (n=122) | Placebo (n=101) | Rovatirelin 2.4 mg (n=101) | Placebo (n=138) | Rovatirelin 2.4 mg (n=140) |
| Age, years               | 62.1±10.6     | 64.3±11.2     | 62.7±10.8     | 66.5±9.0       | 63.5±12.1       | 65.5±9.9       | 64.0±11.5       |
| Sex, n (%)               |               |               |               |               |               |               |               |
| Male                     | 67 (54.5)     | 64 (51.6)     | 64 (52.5)     | 49 (48.5)      | 57 (56.4)       | 73 (52.9)       | 76 (54.3)       |
| Female                   | 56 (45.5)     | 60 (48.4)     | 58 (47.5)     | 52 (51.5)      | 44 (43.6)       | 65 (47.1)       | 64 (45.7)       |
| Disease duration, years  | 9.8±7.3       | 9.9±6.4       | 10.3±7.4      | 9.6±6.6        | 9.9±6.9         | 10.0±6.4        | 11.0±7.8        |
| Type of SCA, n (%)       |               |               |               |               |               |               |               |
| SCA6                     | 42 (34.1)     | 64 (51.6)     | 59 (48.4)     | 44 (43.6)      | 39 (38.6)       | 64 (46.4)       | 56 (40.0)       |
| SCA31                    | 28 (22.8)     | 25 (20.2)     | 19 (15.6)     | 29 (28.7)      | 28 (27.7)       | 35 (25.4)       | 32 (22.9)       |
| CCA                      | 53 (43.1)     | 35 (28.2)     | 44 (36.1)     | 28 (27.7)      | 34 (33.7)       | 39 (28.3)       | 52 (37.1)       |
| Participation in previous rovatirelin study, n (%) |        |               |               | 7 (6.9)        | 7 (6.9)         | 0               | 0               |
| SARA total score, points | 12.78±4.10    | 13.31±4.24    | 12.72±4.83    | 14.70±3.37     | 14.70±3.37      | 15.03±3.71      | 15.36±3.43      |
| <15, n (%)               | 83 (67.5)     | 88 (71.0)     | 84 (68.9)     | 59 (58.4)      | 55 (54.5)       | 67 (48.6)       | 66 (47.1)       |
| ≥15, n (%)               | 40 (32.5)     | 40 (29.0)     | 38 (31.1)     | 42 (41.6)      | 46 (45.5)       | 71 (51.4)       | 74 (52.9)       |

Data are presented as mean±SD unless stated otherwise.

*KPS1301 subgroup (excluding 1.6 mg) and KPS1305 (excluding subject who participated in previous rovatirelin clinical study).

CCA, cortical cerebellar atrophy; SARA, Scale for Assessment and Rating of Ataxia; SCA, spinocerebellar ataxia.

---

**Figure 2**  Adjusted mean and 95% CI of the change in SARA total score from baseline (primary endpoint) in the (A) KPS1301 and (B) KPS1305 studies. P values were calculated using the ANCOVA method. (C) Pooled analysis of patients from KPS1301 and KPS1305 studies who met the KPS1305 inclusion criteria (SARA gait score of 2–6; stance score of ≥2; finger chase, nose–finger and fast alternating hand movement scores of ≥1 each). ANCOVA, analysis of covariance; SARA, Scale for the Assessment and Rating of Ataxia.
greater reductions in fast alternating hand movement scores were observed with rovatirelin 2.4 mg vs placebo (−0.34 vs −0.08; p<0.001).

To test whether rovatirelin was effective in patients with more severe ataxia, the pooled analysis group was divided into two groups using the median baseline SARA total score of 15 as the severity threshold. Patients with a baseline SARA total score ≥15 showed a significantly greater adjusted mean change in SARA total score with rovatirelin 2.4 mg compared with placebo (−1.75 vs −0.58; difference −1.16; 95% CI −1.95 to −0.38; p=0.003). In patients with baseline SARA total score <15, the difference in adjusted mean change in SARA total score between rovatirelin 2.4 mg and placebo was not significant (−1.54 vs −1.48; difference −0.06; 95% CI −0.85 to 0.73; p=0.879). In the placebo group, greater score reductions were observed in patients with a baseline SARA total score <15 than in those with a baseline score ≥15, whereas scores were similar between patients with SARA total score <15 and ≥15 in the rovatirelin 2.4 mg group (figure 3). In patients with SARA total score ≥15, individual SARA scores were significantly reduced with rovatirelin 2.4 mg versus placebo for gait (−0.18 vs 0.13; p=0.025) and fast alternating hand movement (−0.49 vs −0.11, p=0.001).

There were no marked changes from baseline in the SF-8 physical health summary score or mental health summary score in the QoL evaluation for any of the treatment groups (table 2).

**Safety**

The most common treatment-emergent AEs (occurring in ≥5% of patients in both studies) with rovatirelin were nasopharyngitis, nausea, weight loss and contusion (table 3). Common AEs considered to be related to rovatirelin (occurring in ≥5% of patients in any rovatirelin group) were weight loss, nausea and decreased appetite. The majority of AEs were judged to be mild in severity (table 3). AEs leading to treatment discontinuation in 7.2%, 11.9% and 2.4% of patients receiving rovatirelin 1.6 mg, rovatirelin 2.4 mg and placebo, respectively, in KPS1301 (p=0.011, Fisher’s exact test) and 7.9% and 4.9% of patients receiving rovatirelin 2.4 mg and placebo, respectively, in KPS1305 (p=0.407, Fisher’s exact test; table 3).

In patients receiving rovatirelin, mean TSH, FT3, FT4 and PRL levels increased from baseline to week 4; however, the levels were not further increased with continued administration of rovatirelin. These hormone levels exceeded the normal range at some evaluation time points, and mean FT4 levels exceeded the reference value at all evaluation time points (online supplementary tables 2 and 3). Mean FT4 levels returned to baseline values during the follow-up period. The body weight of patients decreased from baseline to final evaluation in each of the rovatirelin groups in KPS1301 (−2.00 kg in the 1.6 mg group, −2.16 kg in the 2.4 mg group and −0.28 kg in the placebo group; p<0.001, one-way analysis of variance) and in the rovatirelin group in KPS1305 (−2.31 kg in the 2.4 mg group vs 0.13 kg in the placebo group; p<0.001 two-sample t-test). No clinically significant changes or findings were observed in vital signs, 12-lead ECG or clinical laboratory tests.

**DISCUSSION**

We found no significant differences in efficacy between rovatirelin and placebo in two prospective randomised controlled studies in patients with predominant cerebellar symptoms of SCD. However, in the pooled analysis of data from the two studies, rovatirelin 2.4 mg was associated with a significantly greater reduction in SARA total score compared with placebo.
**Table 2**  Secondary endpoints

|                        | KPS1301 study | KPS1305 study |
|------------------------|---------------|---------------|
|                        | Placebo (n=123) | Rovatirelin 1.6 mg (n=124) | Rovatirelin 2.4 mg (n=122) | Placebo (n=101) | Rovatirelin 2.4 mg (n=101) |
| **SARA total score, points** |               |               |                           |               |                           |
| Change from baseline at week 4 | –0.52±1.60 | –0.38±1.71 | –0.89±1.41 | –0.50±1.36 | –0.82±1.45 |
| P value (vs placebo) | – | 0.490 | 0.058 | – | 0.105 |
| Change from baseline at week 12 | –0.91±1.89 | –0.88±1.86 | –1.05±1.79 | –0.94±1.97 | –1.43±1.85 |
| P value (vs placebo) | – | 0.930 | 0.565 | – | 0.080 |
| Change from baseline at week 24 | –1.25±2.53 | –0.90±2.04 | –1.23±2.10 | –1.13±2.09 | –1.46±2.19 |
| P value (vs placebo) | – | 0.247 | 0.946 | – | 0.303 |
| Change from baseline at final evaluation | –1.15±2.57 | –0.75±2.05 | –1.22±2.13 | –1.05±2.20 | –1.45±2.12 |
| P value (vs placebo) | – | 0.176 | 0.814 | – | 0.194 |

**SF-8 score, points**

|                        |               |               |                           |               |                           |
|------------------------|---------------|---------------|                           |               |                           |
| PCS at baseline        | 41.82±7.307   | 42.90±7.169   | 42.90±7.623               | 43.38±6.486   | 44.25±6.410               |
| PCS at week 12         | 42.27±7.304   | 41.30±7.546   | 42.27±6.830               | 42.47±7.115   | 43.85±6.776               |
| PCS at week 24         | 42.77±7.184   | 41.44±7.391   | 41.80±7.749               | 41.69±7.147   | 43.85±6.797               |
| PCS at final evaluation| 42.49±7.368   | 41.00±7.627   | 41.02±7.776               | 41.66±7.218   | 43.82±7.589               |
| MCS at baseline        | 48.27±7.136   | 47.49±7.925   | 48.29±7.476               | 47.95±6.739   | 48.06±6.546               |
| MCS at week 12         | 47.00±6.136   | 45.63±6.901   | 45.38±6.804               | 46.38±5.937   | 45.19±7.198               |
| MCS at week 24         | 45.23±6.688   | 44.80±6.966   | 45.17±6.482               | 45.76±6.472   | 44.80±7.588               |
| MCS at final evaluation| 45.13±6.617   | 44.34±7.200   | 44.99±6.418               | 45.74±6.456   | 44.74±7.807               |

Data are presented as mean±SD. Two-sample t-test was used.

MCS, Mental Component Score; PCS, Physical Component Score; SARA, Scale for Assessment and Rating of Ataxia; SF-8, Short Form-8 Health Survey.

**Table 3**  Adverse events (AEs)

|                        | KPS1301 study | KPS1305 study |
|------------------------|---------------|---------------|
|                        | Placebo (n=123) | Rovatirelin 1.6 mg (n=125) | Rovatirelin 2.4 mg (n=126) | Placebo (n=102) | Rovatirelin 2.4 mg (n=101) |
| Any AE, n (%)          | 78 (63.4) | 85 (68.0) | 89 (70.6) | 66 (64.7) | 78 (77.2) |
| AE related to study drug | 12 (9.8) | 37 (29.6) | 45 (35.7) | 16 (15.7) | 33 (32.7) |
| Death                  | 0 | 0 | 0 | 0 | 0 |
| Serious AE             | 5 (4.1) | 1 (0.8) | 6 (4.8) | 3 (2.9) | 4 (4.0) |
| AE leading to treatment discontinuation | 3 (2.4) | 9 (7.2) | 15 (11.9) | 5 (4.9) | 8 (7.9) |

**Severity of AE, * no of events**

|             | Mild | Moderate | Severe |
|-------------|------|----------|--------|
| Any AE (%)  | 167  | 192      | 258    |
| Death (%)   | 13   | 18       | 16     |
| Severe (%)  | 0    | 0        | 4      |

**AE in ≥5% of patients, n (%)**

|                               | KPS1301 study | KPS1305 study |
|-------------------------------|---------------|---------------|
| Nasopharyngitis (%)           | 14 (11.4)     | 16 (12.8)     | 19 (15.1) | 10 (9.8) | 19 (18.8) |
| Nausea (%)                   | 1 (0.8)       | 11 (8.8)      | 14 (11.1) | 1 (1.0) | 9 (8.9) |
| Weight loss (%)              | 0             | 8 (6.4)       | 11 (8.7) | 2 (2.0) | 13 (12.9) |
| Contusion (%)                | 11 (8.9)      | 8 (6.4)       | 8 (6.3)  | 10 (9.8) | 18 (17.8) |
| Periodontitis (%)            | 1 (0.8)       | 2 (1.6)       | 8 (6.3)  | 0       | 2 (2.0) |
| Abdominal discomfort (%)     | 3 (2.4)       | 1 (0.8)       | 7 (5.6)  | 1 (1.0) | 1 (1.0) |
| Cough (%)                    | 2 (1.6)       | 8 (6.4)       | 1 (0.8)  | 1 (1.0) | 4 (4.0) |
| Excoriations (%)             | 3 (2.4)       | 7 (5.6)       | 1 (0.8)  | 1 (1.0) | 2 (2.0) |
| Decreased appetite (%)       | 0             | 2 (1.6)       | 6 (4.8)  | 1 (1.0) | 7 (6.9) |
| Back pain (%)                | 3 (2.4)       | 4 (3.2)       | 2 (1.6)  | 1 (1.0) | 6 (5.9) |
| Insomnia (%)                 | 0             | 0             | 5 (4.0)  | 0       | 5 (5.0) |

**AE leading to treatment discontinuation in ≥2 patients, n (%)**

|                               | KPS1301 study | KPS1305 study |
|-------------------------------|---------------|---------------|
| Nausea (%)                   | 0             | 3 (2.4)       | 1 (0.8)  | 0       | 2 (2.0) |
| Decreased appetite (%)       | 0             | 0             | 2 (1.6)  | 0       | 1 (1.0) |
| Insomnia (%)                 | 0             | 0             | 2 (1.6)  | 0       | 0       |

*The definitions were as follows; mild: normal daily life is not interrupted; moderate: normal daily life is partially interrupted; severe: normal daily life is severely affected.*
(−1.64 vs −1.03; p=0.029) in patients with predominant cerebellar symptoms of SCD. This improvement was more prominent in patients with relatively severe ataxia versus less severe ataxia (−1.75 vs −0.58; p=0.003). We consider this pooled analysis to be valid for the following reasons: (1) pooled data were obtained from identically designed studies; (2) the two studies were conducted within a relatively short period and (3) there was no heterogeneity of patient background between studies (online supplementary figure 2). This pooled analysis allowed us to obtain a more precise estimate of rovatirelin treatment effects and greater statistical power for assessment, indicating that rovatirelin may be a potentially effective treatment option for cerebellar ataxia in patients with predominant cerebellar symptoms of SCD.

The effect of rovatirelin observed in our two individual studies was not significant and showed limited clinical relevance during the 24 weeks treatment period. In fact, both phase 3 studies did not show significant improvements in SF-8 and QoL. However, progression of SCD is generally slow. It has been reported that the annual changes in SARA total score are 0.80–1.33 for SCA6 and 0.8 for SCA31.2 22 23 Considering the sensitivity of SARA and slow progression, limited change in SARA total score was expected during the observation period selected for our study. Furthermore, it should be noted that QoL assessments require long-term observation periods.

Although the patient inclusion criteria for the KPS1305 study were revised based on the positive outcomes of the KPS1301 subgroup analysis, the KPS1305 study did not show any treatment difference between rovatirelin and placebo. Patients in KPS1305 had lower baseline SARA total scores than those in the KPS1301 subgroup (14.9 and 16.8, respectively, p<0.001). Therefore, we hypothesised that patients with less severe ataxia show a more prominent placebo effect. In fact, among patients in the placebo groups, greater SARA score reductions were observed in patients with less severe ataxia than in those with severe ataxia (−1.48 vs −0.58, respectively). On the other hand, in patients receiving rovatirelin, a similar decrease in SARA total score was observed in both groups (−1.54 vs −1.75, respectively). These findings suggest that rovatirelin efficacy was not observed in the KPS1305 study due to the inclusion of a substantial number of patients with mild ataxia and a prominent placebo effect.

It is well known that clinical trials for neurodegenerative diseases often observe a large placebo effect. Our study indicates that the placebo effect should be taken into consideration when evaluating the efficacy of treatments for cerebellar ataxia. Our findings also suggest that the placebo effect can be decreased by restricting treatment to patients with relatively severe ataxia when developing clinical trial protocols for cerebellar ataxia. Although the reason for the prominent placebo effect observed in patients with mild ataxia is unknown, patients with baseline SARA total scores <15 were generally younger and had a shorter disease duration compared with patients with baseline SARA total scores ≥15. One possible reason for this could be that patients with a shorter disease duration may have experienced better improvement with treatment received in the trial. These factors should be kept in mind and carefully considered in clinical trials of ataxia in the future.

In our studies, rovatirelin was associated with increases in thyroid hormone levels to near the upper limits of the reference ranges. Most AEs (eg, nausea and weight loss) were considered to be attributable to these increases in thyroid hormones. However, severe or serious AEs were rare. Treatment discontinuation was more frequent with rovatirelin treatment versus placebo. Common AEs leading to treatment discontinuation were nausea, decreased appetite and insomnia, all of which were of mild or moderate severity. Thus, rovatirelin was considered to have an acceptable tolerability profile. However, long-term AEs with chronic rovatirelin use need to be monitored in future studies.

Drugs for neurodegenerative disease are expected to halt degeneration and improve symptoms.1 Mechanistically, as a TRH analogue, rovatirelin can improve motor function by increasing various neurotransmitter levels1 and having a neuroprotective effect.24 In fact, in a pharmacological study in rats, rovatirelin increased locomotor activity associated with increased noradrenaline concentration,2 as a result of its rapid absorption, stability in plasma and transition into the brain.13 Further investigation is necessary to examine whether rovatirelin can inhibit the progression of SCD with long-term treatment.

Our studies only included patients with predominant cerebellar symptoms of SCD. The molecular pathogenesis of cerebellar degeneration in predominant cerebellar symptoms of SCD includes abnormal elongation of CAG repeat sequences in the CACNA1A gene in SCA6,25 augmentation of the (TGGA)n sequence located in an intron in SCA326 and mixed mechanisms in CCA.27 The fact that rovatirelin showed efficacy in these conditions indicates that this drug exerts a beneficial effect on cerebellar function as a whole. This suggests that rovatirelin may improve motor function in patients with extracerebellar symptoms of SCD.

Our studies have several limitations. Although improvements in SARA total score were found in pooled and subgroup analyses, these analyses were post hoc in nature. The studies included only Japanese patients, which may influence the generalisability of results. Although the number of repeats can influence the clinical severity of SCA6 and SCA31, data on the number of repeats were not obtained. However, as the effect of the number of repeats on the pathological condition is often subtle in these diseases, this lack of data was considered to be inconsequential.2 23 28 As genetic analyses were not essentially required for CCA diagnosis, it is possible that patients with SCA6, SCA31 or other genetic disorders were included in these studies.

CONCLUSION
In two large-scale double-blind studies in patients with predominant cerebellar symptoms of SCD, rovatirelin was not associated with a statistically significant change in SARA total score compared with placebo; however, the pooled analysis of patients with both truncal and limb ataxia indicated that rovatirelin is a potentially effective treatment option against cerebellar ataxia in patients with predominant cerebellar symptoms of SCD. This improvement was more prominent in patients with relatively severe ataxia than in those with less severe ataxia. Further studies are needed to assess the long-term efficacy and safety of rovatirelin, as well as patient-reported outcomes.

Acknowledgements Statistical analyses were completed by MY, Kissei Pharmaceutical, Bunkyo-ku, Tokyo, Japan. We thank Yoshiko Okamoto, inScience Communications, Springer Healthcare for providing editorial support and Toni Dando and Sarah Greif, of inScience Communications, Springer Healthcare for editing and styling the manuscript for submission. This medical writing assistance was funded by Kissei Pharmaceutical.

Collaborators The Rovatirelin Study Group included following physicians: Takao Hashimoto (Aizawa Hospital), Masashiro Sugawara (Akita University Hospital), Masahiko Tomyama (Aomori Prefectural Central Hospital), Kazuhiro Takanatsu (Brain Attack Center Ota Memorial Hospital), Masaru Kurijima (Brain Attack Center Ota Memorial Hospital), Shigeki Hirano (Chiba University Hospital), Takahide Nagashima (Dokkyo Medical University Hospital), Kenso Okamoto (Ehime

Nishizawa M, et al. J Neurol Neurosurg Psychiatry 2020;91:1–9. doi:10.1136/jnnp-2019-322168
Contributors

NN, OO and YS contributed to the concept or design of the study. MY analysed the study data. All authors contributed to the data interpretation and writing of the manuscript and approved the final version of the manuscript.

Funding

Kissei Pharmaceutical funded the studies and was involved in designing the study, data collection, data analysis, data interpretation and writing of the report. The corresponding author had full access to all the data in the studies and had final responsibility for the decision to submit for publication.

Competing interests

MN has received grants and personal fees from Kissei Pharmaceutical during the conduct of the study, and has received grants and personal fees from Astellas Pharma, Daiichi-Sankyo, Sumitomo Dainippon, Eisai, FP, GlaxoSmithKline, Japan Blood Products Organization, Kyowa Hakko Kirin, Mitsubishi Tanabe, MSD, Novartis, Otsuka, Pfizer, Sanofí, and Takeda, outside the submitted work. OOO has received grants and personal fees from Kissei Pharmaceutical during the conduct of the study, and has received grants and personal fees from Astellas Pharma, Boehringer Ingelheim, Daiichi-Sankyo, Eisai, Eli Lilly, FP, GlaxoSmithKline, Japan Blood Products Organization, Kyowa Hakko Kirin, Mitsubishi Tanabe, MSD, Novartis, Otsuka, Pfizer, Sanofí, Shionoji, Sumitomo Dainippon and Takeda, outside the submitted work. AH has received personal fees from Kissei Pharmaceutical during the conduct of the study. YS and MY are employees of Kissei Pharmaceutical. YS has a patent P2017-14198A issued.

Patient consent for publication

Not required.

Ethics approval

These studies were implemented based on ethical principles expressed in Good Clinical Practice (GCP) and the Declaration of Helsinki. Implementation of these studies was approved by the institutional review board of each facility prior to the start of the studies. Written informed consent was obtained from each patient.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iD

Masatoyo Nishizawa http://orcid.org/0000-0001-9442-6827

REFERENCES

1. Ashizawa T, Oz G, Paulson HL. Spinocerebellar ataxias: prospects and challenges for therapy development. Nat Rev Neurol 2018;14:590–605.
2. Jacobs I, de Montell ST, Bauer P, et al. Long-Term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol 2015;14:1101–8.
3. Klokopper T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Primers 2019;5:24.
4. Horita A. An update on the CNS actions of TRH and its analogues. Life Sci 1998;62:1443–8.
5. Griffiths EC. Clinical applications of thyrotropin-releasing hormone. Clin Sci 1987;73:449–57.
6. Horita A, Carino MA, Lai H. Pharmacology of thyrotropin-releasing hormone. Annu Rev Pharmacol Toxicol 1986;26:311–32.
7. O’Leary R, O’Connor B. Thyrotropin-Releasing hormone. J Neurochem 1995;65:953–63.
8. Muroga T, Adachi K, Konaga M, et al. Effects of thyrotropin releasing hormone on cerebellar mutant mice—a kinesiological comparison between rolling mouse Niigata, weaver and reeler. Jpn J Med 1982;21:101–8.
9. Shibisawa N, Hashimoto K, Yamada M. Thyrotropin-Releasing hormone (TRH) in the cerebellum. Cerebellum 2008;7:84–95.
10. Soubi T, Takayama T, Nakashita T, et al. Controlled trial of thyrotropin releasing hormone tartrate in ataxia of spinocerebellar degenerations. J Neurol Sci 1983;61:235–48.
11. Ogawa M. Pharmacological treatments of cerebellar ataxia. Cerebellum 2004;3:107–11.
12. Ziesche IA, Wilmot G, Kuo S-H, et al. Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia: report of the Guideline development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018;90:464–71.
13. Kobayashi N, Sato N, Fujimura Y, et al. Discovery of the Orally Effective Thyrotropin-Releasing Hormone Mimetic: 1-(N-(44,55)-(S)-Methyl-2-oxoazolidine-4-yl-carbonyl)-3-(thioxo-4-yl)-1-allyl)-2H-2-methylpyrrolidine-1-trihydrate (Rovatirelin Hydrate). ACS Omega 2018;3:13647–46.
14. Ijiro T, Nakamura K, Ogata M, et al. Effect of rovatirelin, a novel thyrotropin-releasing hormone analogue, on the central noradrenergic system. Eur J Pharmacol 2015;761:413–22.

Nishizawa M, et al. J Neurol Neurosurg Psychiatry 2020;0:1–9. doi:10.1136/jnnp-2019-322168

Prepared by copyright.
Kobayashi K, Abe Y, Harada H, et al. Non-Clinical pharmacokinetic profiles of rovatirelin, an orally available thyrotropin-releasing hormone analogue. Xenobiotica 2019;49:106–19.

Yoshida K, Kuwabara S, Nakamura K, et al. Idiopathic cerebellar ataxia (IDCA): diagnostic criteria and clinical analyses of 63 Japanese patients. J Neurol Sci 2018;384:30–5.

Gilman S, Werning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670–6.

Schmitz-Hübsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717–20.

Sato K, Yabe I, Soma H, et al. Reliability of the Japanese version of the Scale for the Assessment of Ataxia (SARA). Brain Nerve 2009;61:591–5.

Fukuhara S, Suzukamo Y. Manual of the SF-8 Japanese Version [in Japanese]. Kyoto: Institute for Health Outcomes and Process Evaluation Research, 2004.

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.ICH Harmonised tripartite guideline E9: statistical principles for clinical trials, 1998. Available: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf (Accessed 19 July 2019).

Yasui K, Yabe I, Yoshida K, et al. A 3-year cohort study of the natural history of spinocerebellar ataxia type 6 in Japan. Orphanet J Rare Dis 2014;9:118.

Nakamura K, Yoshida K, Matsushima A, et al. Natural history of spinocerebellar ataxia type 31: a 4-year prospective study. Cerebellum 2017;16:518–24.

Ishida Y, Kawakami H, Kitajima H, et al. Vulnerability of Purkinje cells generated from spinocerebellar ataxia type 6 patient-derived iPSCs. Cell Rep 2017;18:1075–6.

Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997;15:62–9.

Sato N, Amino T, Kobayashi K, et al. Spinocerebellar ataxia type 31 is associated with “inserted” pentanucleotide repeats containing (TGGAA)n. Am J Hum Genet 2009;85:544–57.

Tsujii S, Onodera O, Goto J, et al. Sporadic ataxias in Japan—a population-based epidemiological study. Cerebellum 2008;7:189–97.

Ishikawa K, Tanaka H, Saito M, et al. Japanese families with autosomal dominant pure cerebellar ataxia map to chromosome 19p13.1-p13.2 and are strongly associated with mild CAG expansions in the spinocerebellar ataxia type 6 gene in chromosome 19p13.1. Am J Hum Genet 1997;61:336–46.